Search Results
22 Results Found for “cutaneous squamous cell carcinoma”
An immunosuppressed person is one whose immune function is impaired by underlying disease and/or immunosuppressive medications, resulting in reduced immunosurveillance against malignant cells and increased vulnerability to opportunistic infections. Longstanding immunosuppression has been linked to increased risk for cutaneous (...
The first half of 2025 has brought exciting developments in oncology, with groundbreaking research and real-world progress showcased at ASCO, EHA and many more leading conferences around the world. We asked five of our touchONCOLOGY Future Leaders 2025 to share what they believe has been most impactful so far this year – here’s what they told us.
"While groundbreaking treatments are transformative, patients often remember the kindness and humanity of their oncologist more than the medicine they receive" Introducing our Future Leaders series, in this interview Dr Rodrigo Munhoz (Oncology Center – Hospital SÃrio-Libanês in Sã...
Sarcomas are a diverse group of rare muscle, bone and connective tissue tumours. Within soft-tissue sarcoma alone, there are over 70 subtypes, which demonstrate substantial heterogeneity in biology, genetics and clinical behaviour.1Â Further complicating their management is the range of treatment ...
The antitumor activity of immune checkpoint inhibotors in various solid and haematologic malignancies has substantially increased immunotherapy implications for cancer. Once only a niche treatment for selected cancers (renal cancer and melanoma), now cancer immunotherapy has become an important option ...
Professor Paolo A. Ascierto is Director of the Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics at the National Tumor Institute, Naples, Italy. Â He obtained his medical degree from the University of Naples, the same institution where he subsequently earned ...
Bladder cancer is the ninth most common cancer worldwide, with an estimated 430,000 new cases and 165,000 deaths in 2012.1 More than 90% of bladder cancers are of urothelial cell origin and the remaining histological subtypes include either pure forms of histological variants, such ...
It has been clearly established that non-small cell lung cancers (NSCLCs) associated with known molecular drivers (e.g., rearrangement of the ALK gene, or mutations activating the epidermal growth factor receptor [EGFR] gene) respond favorably to targeted, first-line therapies compared ...
Metastatic melanoma management has been transformed in the past few years, with the development of new therapeutic options that provide significant survival benefits replacing palliative chemotherapy. One aspect of this advance has been an increased understanding of molecular aberrations in ...
Polycythaemia vera (PV) is a chronic myeloproliferative neoplasm characterised by unregulated proliferation of red blood cells, and sometimes leukocytes and platelets in the absence of a recognisable physiological stimulus.1–4 Increased red blood cell mass leads to hyperviscosity of the blood ...
In 1777, Maximilian de Stoll, a Viennese surgeon published the first credited description of gallbladder cancer. Over two centuries later, gallbladder cancer remains a difficult disease with a dismal prognosis for those patients with advanced disease. Historically described as an extrahepatic ...
Anaplastic Lymphoma Kinase Anaplastic Lymphoma Kinase Located at 2p23, the anaplastic lymphoma kinase (ALK) gene codes for a receptor tyrosine kinase (RTK). This gene was initially identified in the chimeric nucleophosmin (NPM)-ALK fusion driven by the t(2;5)(p23;q35), ...
Although some haematological malignancies such as Hodgkin’s lymphoma (HL) or acute myeloiud leukaemia (AML) are curable with conventional treatments, many patients still relapse, and these relapses are more resistant to therapy than the original disease. Moreover, other diseases, such ...
‘Epigenetics’ is a term used to describe heritable states of gene expression that are not due to changes in DNA sequence. Epigenetic phenomena have been shown to play an important role in carcinogenesis and tumor progression. Such phenomena also represent ...
Docetaxel is effective against numerous tumours, mainly in metastatic breast cancers; however, it can lead to other conditions, in particular cutaneous reactions, such as onycholysis and hand–foot syndrome. The ungual toxicity of docetaxel is well-known and occurs in 40–50% of ...
Lung cancer is a major global health burden: it was responsible for 1.3 million deaths in 2004, equating to 2.3% of all deaths. Death rates from lung cancer are predicted to continue to rise, with the disease being responsible for 2.8% of all deaths (1.67 ...
Colorectal cancer is the third most common cancer worldwide and the second leading cause of cancer deaths in the developed world,1,2 with an estimated 149,000 new cases and 50,000 deaths each year in the US.3 Considerable progress has been achieved in the ...
Lung cancer is the main cause of cancer deaths for both men and women in the US and worldwide. In the US, there were approximately 232,270 new cases diagnosed and 166,280 deaths due to this disease by the end of 2008.1 Non-small-cell cancer (...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
